Skip to main content
Advertisement

Main menu

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • About Us
    • About AJNR
    • Editorial Board
    • American Society of Neuroradiology
  • For Authors
    • Author Policies
    • Manuscript Submission Guidelines
  • Submit a Manuscript
  • Podcasts
    • Podcasts
    • Subscribe on iTunes
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback

User menu

  • Subscribe
  • Alerts
  • Log in

Search

  • Advanced search
American Journal of Neuroradiology
American Journal of Neuroradiology

American Journal of Neuroradiology

  • Subscribe
  • Alerts
  • Log in

Advanced Search

  • Home
  • Content
    • Current Issue
    • Publication Preview--Ahead of Print
    • Past Issue Archive
    • Case of the Week Archive
    • Classic Case Archive
    • Case of the Month Archive
    • COVID-19 Content and Resources
  • About Us
    • About AJNR
    • Editorial Board
    • American Society of Neuroradiology
  • For Authors
    • Author Policies
    • Manuscript Submission Guidelines
  • Submit a Manuscript
  • Podcasts
    • Podcasts
    • Subscribe on iTunes
  • More
    • Subscribers
    • Permissions
    • Advertisers
    • Alerts
    • Feedback
  • Follow AJNR on Twitter
  • Visit AJNR on Facebook
  • Follow AJNR on Instagram
  • Join AJNR on LinkedIn
  • RSS Feeds
Research ArticleINTERVENTIONAL

Superselective Intra-Arterial Ethanol Sclerotherapy of Feeding Artery and Nidal Aneurysms in Ruptured Cerebral Arteriovenous Malformations

F. Settecase, S.W. Hetts, A.D. Nicholson, M.R. Amans, D.L. Cooke, C.F. Dowd, R.T. Higashida and V.V. Halbach
American Journal of Neuroradiology April 2016, 37 (4) 692-697; DOI: https://doi.org/10.3174/ajnr.A4584
F. Settecase
aFrom the Division of Interventional Neuroradiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for F. Settecase
S.W. Hetts
aFrom the Division of Interventional Neuroradiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for S.W. Hetts
A.D. Nicholson
aFrom the Division of Interventional Neuroradiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for A.D. Nicholson
M.R. Amans
aFrom the Division of Interventional Neuroradiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for M.R. Amans
D.L. Cooke
aFrom the Division of Interventional Neuroradiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for D.L. Cooke
C.F. Dowd
aFrom the Division of Interventional Neuroradiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for C.F. Dowd
R.T. Higashida
aFrom the Division of Interventional Neuroradiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for R.T. Higashida
V.V. Halbach
aFrom the Division of Interventional Neuroradiology, Department of Radiology and Biomedical Imaging, University of California, San Francisco, San Francisco, California.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for V.V. Halbach
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

SUMMARY: In the endovascular treatment of cerebral arteriovenous malformations, ethanol sclerotherapy is seldom used due to safety concerns. However, when limited reflux of an embolic agent is permissible or when there is a long distance to the target, ethanol may be preferable. We reviewed 10 patients with 14 cerebral AVM feeding artery aneurysms or intranidal aneurysms treated with intra-arterial ethanol sclerotherapy at our institution between 2005 and 2014. All patients presented with acute intracranial hemorrhage. Thirteen of 14 aneurysms were treated primarily with 60%–80% ethanol into the feeding artery. Complete target feeding artery and aneurysm occlusion was seen in all cases; 8/13 (62%) were occluded by using ethanol alone. No retreatments or recurrences were seen. One permanent neurologic deficit (1/13, 7.7%) and no deaths occurred. In a subset of ruptured cerebral AVMs, ethanol sclerotherapy of feeding artery aneurysms and intranidal aneurysms can be performed with a high degree of technical success and a low rate of complication.

ABBREVIATIONS:

FAA
feeding artery aneurysm
EtOH
ethanol
INA
intranidal aneurysm

Aneurysms are often seen in association with cerebral arteriovenous malformations, occurring either along an artery supplying the AVM, within the AVM nidus, or arising from an unrelated artery. Flow-related feeding artery aneurysms and intranidal aneurysms are a primary source of hemorrhage in ruptured cerebral AVMs.1⇓–3 Currently, treatment options for cerebral AVMs include surgery, stereotactic radiosurgery, and endovascular embolization, each of which may be performed as a stand-alone therapy or in combination. Embolization alone is rarely curative, and its primary role is to promote safer surgical resection by decreasing blood loss, shortening the length of surgery, reducing the risk of damage to surrounding structures, and increasing the likelihood of complete resection. Embolization may also render an AVM more amenable to radiosurgery by reducing the size of the AVM nidus and can be used to treat feeding artery or intranidal aneurysms, especially if deep-seated and difficult to access or control surgically.4⇓⇓–7

Embolization of an AVM requires superselective catheterization and distal placement of the microcatheter within a feeding artery, aiming to protect the parent artery from any reflux of embolic material and any en passage branches from nontarget embolization. The most commonly used embolic material is n-butyl cyanoacrylate, a quickly polymerizing liquid adhesive. Ethylene vinyl copolymer (Onyx; Covidien, Irvine, California)8⇓–10 is a newer but less commonly used embolic agent in AVM treatment. Particles11 and detachable coils are infrequently used.

Ethanol sclerotherapy is commonly used in the treatment of extracranial AVMs,12⇓⇓–15 yet it is seldom used in the treatment of cerebral AVMs due to safety concerns.16⇓⇓⇓⇓⇓⇓⇓⇓–25 In some circumstances, such as when distal microcatheter positioning beyond the proximal portion of a small feeding artery is not possible, however, the use of ethanol may be preferable. In this retrospective case series, we report our experience with patients whose brain AVMs presented with acute intracranial hemorrhage in whom ethanol sclerotherapy was preferable to other embolization techniques to treat feeding artery aneurysms (FAAs) or intranidal aneurysms (INAs).

Case Series

Under an institutional review board–approved protocol, a keyword search of the University of California, San Francisco neurointerventional data base identified 10 patients with cerebral AVMs and associated FAAs or INAs treated by using super selective intra-arterial ethanol sclerotherapy between 2005 and 2014. Neuroimaging, angiograms, operative reports, and electronic medical records were reviewed for each patient by a board-certified radiologist with a Certificate of Added Qualification in neuroradiology, 2 years' work experience in diagnostic neuroradiology, and additional training in interventional neuroradiology (F.S.).

After presentation with intracranial hemorrhage and CT and/or CT angiographic evidence of an underlying cerebral arteriovenous malformation, patients were referred to the interventional neuroradiology service for diagnostic cerebral angiography. Indications for AVM endovascular embolization were determined by clinical presentation, cross-sectional imaging, and angiographic findings. In all cases in this series, the decision to proceed with embolization was determined by the presence of intracranial hemorrhage in the setting of a cerebral AVM and the presence of either a FAA or INA suspected as the hemorrhage source and/or at risk for future hemorrhage (Figs 1 and 2). Indications for treatment and treatment strategy were agreed upon by the attending neuroradiologist (V.V.H.) and the admitting neurosurgeon in all cases. In all cases, the primary goal of treatment was obliteration of the FAA or INA. AVM nidus-size reduction or obliteration was a secondary goal. All patients consented to the use of a number of possible embolic materials as well as ethanol. The decision to use ethanol was made during the procedure, after obtaining superselective distal catheter positioning and on the basis of several factors, including the following: distance from the microcatheter tip to the target aneurysm, position of the catheter just beyond a branch point in which 1 branch was en passage to normal brain (eg, catheter positioned in the origin of the posterolateral choroidal artery), and amount of flow present within the feeding artery before treatment. For the concentration and volume of ethanol, we also took into account the above factors. In addition, serial angiograms were obtained midsclerotherapy to determine the efficacy of ethanol sclerotherapy and whether additional volume or change in the concentration of ethanol was necessary. In cases in which residual flow within the feeding artery and incomplete aneurysm occlusion were seen, adjunctive endovascular therapies were performed, such as coil placement or n-butyl cyanoacrylate embolization.

Fig 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 1.

Ethanol sclerotherapy of a feeding artery aneurysm in a 5-year-old girl with a right thalamic AVM. A, Lateral view, left vertebral artery injection demonstrates an 11-mm feeding artery aneurysm (arrow) arising from the right posterolateral choroidal artery at the posterior aspect of the AVM nidus. B, Superselective microcatheter injection of the right posterolateral choroidal artery again demonstrates the feeding artery aneurysm. Note that the microcatheter is positioned in the proximal portion of right posterolateral choroidal artery. More distal catheterization of this artery was not possible. C, Lateral view left vertebral artery injection 20 minutes after intra-arterial sclerotherapy with 5 mL of 70% ethanol demonstrates lack of filling of the feeding artery and aneurysm. D, Unsubtracted lateral view of the skull at the end of the sclerotherapy treatment demonstrates stasis of contrast within the aneurysm.

Fig 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig 2.

Ethanol sclerotherapy of a feeding artery aneurysm in a 15-year-old girl presenting with headache. A, Noncontrast CT head axial image demonstrates acute intraparenchymal hemorrhage centered in the splenium of the corpus callosum with intraventricular extension. B, Selective injection of the left vertebral artery in a reverse Schuller projection demonstrates a small AVM nidus (open arrow) and a 5-mm feeding artery aneurysm arising from the right splenial artery (black arrow). C, Lateral view of a superselective microcatheter injection of the right splenial artery. The AVM nidus (open arrow) and a 5-mm feeding artery aneurysm (black arrow) are again seen. D, Twenty minutes after ethanol sclerotherapy with 4 mL of 70% ethanol, posttherapy reverse Schuller projection of a left vertebral artery injection demonstrates the absence of the feeding artery aneurysm and AVM nidus and no evidence of arteriovenous shunting.

Noncontrast head CTs were reviewed to determine the presence and location of intracranial hemorrhage. Angiograms were reviewed to score the AVM grade and to determine the AVM location, the presence and number of feeding arteries or nidal aneurysms, the feeding artery from which the aneurysm arose, and the presence or absence of aneurysm filling on posttreatment runs. AVM size was estimated from MR imaging and angiography, and all AVMs were classified according to the Spetzler-Martin grading scale.26 The clinical status of patients was assessed at presentation, after embolization, and throughout hospitalization by members of the interventional neuroradiology and neurosurgical teams; and at follow-up visits by a neurosurgeon. Ethanol sclerotherapy was performed in all patients. Operative reports were reviewed to determine the aneurysm size, percentage of ethanol concentration used, amount of ethanol injected, adjunctive treatments, and periprocedural complications. The electronic medical record and follow-up digital subtraction angiograms were reviewed to determine the number of treatment sessions, aneurysm recurrence, delayed complications or death, definitive AVM treatments, and duration of follow-up. No clinical or angiographic follow-up was available in 1 patient.

Endovascular Procedure

Informed consent was obtained from the patient or family before diagnostic angiography and possible endovascular therapy, including possible ethanol sclerotherapy. Potential risks discussed included those directly related to the procedure and those related to general anesthesia. All procedures were performed on a biplane angiographic unit with the patient under general anesthesia (with neuromuscular blockade administered and confirmed just before ethanol injection). Arterial lines were placed in each patient. Percutaneous vascular access was obtained through the right or left common femoral artery by using a standard coaxial technique. A complete cerebral angiogram that included both internal carotid arteries, the dominant vertebral artery, and, in some cases, the ipsilateral external carotid artery was obtained before treatment to identify the arterial feeders of the AVM. After a decision to treat was made and following any necessary upsizing of the vascular groin sheath, an intravenous bolus of 70 IU/kg body weight of heparin was administered and postheparin activated clotting time was obtained. A half dose of the initial bolus dose of IV heparin was administered at 1-hour intervals during the embolization procedure.

A guiding catheter was placed into the ipsilateral internal carotid artery or dominant vertebral artery; then, either a flow-directed microcatheter or an over-the-wire microcatheter was advanced under fluoroscopic and roadmap guidance into the AVM feeding artery branch. No provocative testing was performed. The microcatheter was positioned as distally as possible within the feeding artery to rest as close as possible to the AVM nidus or in a position for embolizing the feeding artery aneurysm while avoiding nontarget en passage branch embolization. Once an adequate microcatheter position was obtained, the microcatheter was flushed with 0.3–0.5 mL of heparinized normal saline. Dehydrated absolute ethanol was drawn into a 1-mL Luer lock syringe and mixed with varying amounts of heparinized iohexol contrast (Omnipaque 300; GE Healthcare, Piscataway, New Jersey) to achieve the desired final concentration of ethanol for sclerotherapy. Short, gentle pulsed injections of ethanol were performed via the microcatheter under roadmap blank fluoroscopic monitoring, aiming to avoid reflux. After delivery of 1–2 mL of the ethanol-contrast mixture, 10–20 minutes were allowed to elapse before performing a midembolization angiographic run through the microcatheter to allow ethanol to take effect on the arterial endothelium. Midsclerotherapy runs were then performed to determine whether any residual filling of the aneurysm or upstream feeding artery remained. In some cases, additional volumes of ethanol-contrast mixtures were administered and, after another 10- to 20-minute delay, angiography was repeated. If no further contrast filling of the aneurysm and upstream feeding artery was seen, no further sclerotherapy or adjunctive embolization was performed. In some cases, residual filling of the feeding artery and aneurysm was observed, and adjunctive therapies such as placement of detachable coils or injection of n-BCA was performed.

Patients

From 2005 to 2014, 10 patients with a ruptured cerebral AVMs and associated FAAs or INAs were treated at our hospital by using superselective intra-arterial ethanol sclerotherapy. There were 5 males and 5 females, with a mean age of 25 ± 21 years (median, 15 years; range, 1–64 years). All patients underwent CT, MR imaging, and digital subtraction angiography. Clinical presentation included intraventricular hemorrhage in all patients, intraparenchymal hemorrhage in 8/10 patients, and subarachnoid hemorrhage in 4/10 patients. The AVM Spetzler-Martin grades ranged from II to IV (Table). Aneurysm sizes ranged from 1 to 11 mm (average size, 4 ± 2.4 mm).

View this table:
  • View inline
  • View popup

Patient demographics, AVM, and flow-related aneurysm characteristics

Results

Fourteen feeding artery or intranidal aneurysms were identified in 10 patients, of which, 13 were treated with superselective intra-arterial ethanol sclerotherapy (On-line Table). One of the 14 aneurysms was not treated due to its location (arising from the calcarine artery with several en passage branches). Mixtures of 60%–80% ethanol (70% ethanol was used in 7/10 patients) were delivered slowly under roadmap-mask guidance directly into the feeding artery supplying the aneurysm. Posttherapy angiography to assess aneurysm occlusion was performed 10–20 minutes after ethanol injection. The volume of ethanol injected ranged from 2 to 22 mL (median, 3.75 mL) (Table). Complete occlusion of the aneurysm and upstream feeding artery was seen in 13/13 treated aneurysms (100%) (Figs 1 and 2), with 8/13 (62%) aneurysms occluded by using ethanol sclerotherapy alone. In addition, ethanol sclerotherapy alone achieved both aneurysm occlusion and angiographic cure of the AVM in 2 cases (On-line Table, Fig 2).

Adjunctive endovascular interventions were performed after ethanol sclerotherapy to treat 5/13 (38%) aneurysms in 4 patients. After ethanol sclerotherapy of 4 aneurysms, markedly decreased but residual blood flow in the feeding artery remained on post-ethanol (EtOH) angiography. To promote complete thrombo-occlusion of the feeding artery, we placed detachable coils within the feeding artery in 4/5 aneurysms from the same microcatheter tip location as in the EtOH injection. In another patient, after an injection of 5 mL of 60% ethanol and another 5 mL of 80% ethanol into the feeding artery, slowed but persistent flow within the feeding artery and FAA was seen postsclerotherapy. During the same treatment session, 0.3 mL of 20% n-BCA was used to embolize the aneurysm, feeding artery, and AVM nidus with no residual AVM or aneurysm filling after n-BCA embolization.

Follow-up was available in 9/10 patients, with a mean follow-up of 1.3 years (range, 3 months to 5 years). None of the treated aneurysms required >1 treatment session, and there were no recurrences. One complication related to ethanol sclerotherapy was encountered (1/13, 7.7%): This patient developed transient hemiparesis and aphasia after injection of 6 mL of 70% ethanol into a posterolateral choroidal artery feeding artery with a 3-mm FAA in a Spetzler-Martin grade IV left frontoparietal AVM. At 5-year follow-up, the hemiparesis had nearly completely resolved with motor examination notable for 4+/5 strength in the tibialis anterior. His aphasia had also improved; however, he exhibited hesitant speech with paraphasic errors. No deaths were attributed to ethanol sclerotherapy in both the periprocedural and follow-up periods.

Discussion

Our experience by using ethanol sclerotherapy for feeding artery aneurysms and intranidal aneurysms in a subset of ruptured cerebral AVMs demonstrates that complete aneurysm and upstream feeding artery occlusion may be achieved in most cases (62%) with ethanol alone. Ethanol is a potent sclerosant, is relatively inexpensive, and has a widespread commercial availability. The injection of small volumes of high concentrations of ethanol results in the dehydration, precipitation, sloughing, and denudation of the vascular endothelium.16,19,27,28 In the presence of blood, an acute thrombosis may be initiated, leading to permanent vascular closure.16,27

In 5/13 aneurysms, ethanol sclerotherapy markedly reduced blood flow within the feeding artery; however, slow contrast filling of the aneurysm persisted and adjunct endovascular therapy was necessary for complete occlusion of the aneurysm and feeding artery. Adjunctive therapies included placement of 2 detachable coils or a fibered coil into the feeding artery from the same microcatheter tip location as that used for the EtOH injection or n-BCA embolization of the feeding artery (On-line Table). No correlation was found between the need for adjunct endovascular therapy (ie, coils or n-BCA) and the size of the flow-related aneurysm or AVM or ethanol concentration or volume. Because EtOH acts directly on endothelial cells, factors that decrease the amount of time the EtOH dwells in the artery and is in contact with endothelium, such as feeding artery diameter and rate of AV shunting, are more likely to result in incomplete occlusion with EtOH alone. Nonetheless, 1 embolization session was sufficient to obtain complete obliteration for all 13 aneurysms, and no recurrences were seen after a mean follow-up of 1.3 years.

In our study, 1 complication (1/13 treated aneurysms, 7.7%) occurred after ethanol sclerotherapy of a posterolateral choroidal feeding artery to the AVM, with periatrial white matter low attenuation seen on postoperative CT, likely due to a combination of vasogenic and cytotoxic edema of nontarget brain tissue. No deaths were attributed to ethanol sclerotherapy. An initial report of ethanol sclerotherapy of cerebral AVMs by Yakes et al16 described permanent complications developing in 8 of 17 (47%) patients, of which 3 were permanent (18%) and 5 (29%) were transient complications, and 2 deaths (2/17, 12%) occurring at 4 and 14 months after ethanol treatment due to subarachnoid hemorrhage. The very high complication rate reported in that study has limited the use of ethanol in the treatment of cerebral AVMs. Since the study of Yakes et al,16 there have been no other published reports of the use of ethanol sclerotherapy of cerebral AVMs. Ethanol sclerotherapy continues to be routinely used, however, in the treatment of peripheral AVMs.29

The results of this study differ from those of the study by Yakes et al16 in several ways: First, in our study, the primary goal of therapy in each patient was obliteration of the feeding artery aneurysm or intranidal aneurysm, whereas AVM nidus obliteration or reduction in size of the AVM nidus was the primary goal in the Yakes et al16 study. The average volume of ethanol used was, therefore, much lower in our study (ie, 2–22 mL; median, 3.75 mL versus 0.8–112 mL); this difference may have contributed to a lower complication rate. Second, ethanol concentrations used in our study varied from 60% to 80%, compared with 98% ethanol used in the prior study. Yakes et al stated that nonionic contrast medium can be mixed with ethanol and precipitation does not occur; however, contrast media dilute ethanol to a level that renders it ineffective in achieving a sclerosing effect and thrombosis. In contrast, this study indicates that concentrations of 60%–80% ethanol have a potent sclerosing effect. Third, the presenting symptoms in our study were also different, with all AVMs in our study presenting with intracranial hemorrhage, whereas presentation varied in the prior study (hemorrhage in 7/17 patients, seizures, hemianopsia, headaches, trigeminal neuralgia, and thalamic syndrome).

Despite the encouraging results of intra-arterial ethanol sclerotherapy demonstrated in this study in the setting of flow-related aneurysms in ruptured AVMs, we do not recommend routine use of this agent in the endovascular treatment of AVMs. Embolic materials such as n-BCA or Onyx remain first-line agents in the endovascular treatment of AVMs in our practice. In each case within this series, the choice of embolic agent versus sclerosant was not made a priori, rather only after superselective microcatheterization and distal access (or attempted distal access) of the feeding artery. The cases included in this series demonstrate that there are rare circumstances in which ethanol may be preferable to embolic agents—for example, when superselective catheterization, which minimizes the risk of reflux and nontarget embolization, is not possible, such as with an inability to position a microcatheter beyond the proximal portion of a small feeding artery (Fig 1; cases 1, 2, 4, 7, and 8). While reflux of an embolic agent into the parent artery in this situation could have devastating consequences, the risk of nontarget vascular injury from reflux of ethanol from the same vessel is decreased because ethanol concentration drops in the parent artery via dilution. A second scenario in which ethanol was preferable to embolic agents occurred when a particularly long distance between the microcatheter tip and the target aneurysm existed and there was substantial risk of a standard liquid embolic agent not reaching the target (cases 1–5, 7–10). Consideration should also be given to the surgical accessibility of FAA or INA if endovascular therapy is being performed preoperatively. The AVM itself or many of the FAAs/INAs in this case series were deep-seated; this location favored endovascular over surgical treatment of the flow-related aneurysms. Careful consideration of the indications for treatment, efficacy, and risks of embolization materials (n-BCA and Onyx) and ethanol must be made before treatment and once the final microcatheter position in the feeding artery is attained.

Extreme caution should be used when injecting ethanol in any concentration or amount due to the high toxicity of ethanol. Nontarget necrosis of adjacent tissues may occur with overinjection, localized extravasation, or reflux.16,20 In addition, ethanol may exert effects distant from the target site, including the venous system causing a thrombophlebitis; or (in larger quantities) more distant effects of intoxication, hemoglobinuria, pulmonary artery hypertension, pulmonary embolus, bronchospasm, hyperthermia, cardiopulmonary collapse, and death.16,18⇓⇓⇓⇓⇓⇓–25 Ethanol sclerotherapy has also been associated with disruption in coagulation profiles as evidenced by a decrease in platelets and fibrinogen, an increase in prothrombin time, and a conversion from negative to positive D-dimers.30 In 1 case report, the bispectral index, a measure of the depth of anesthesia, fell to zero during ethanol sclerotherapy of a cerebral AVM.31 Therefore, great care should be taken to not exceed a per-procedure administered dose of >1 mL/kg.27 This study shows that volumes well below this threshold are efficacious (Table); however, close patient monitoring for the above adverse events and complications following ethanol sclerotherapy should always be performed.

In addition to the above effects, our group has also reported intraventricular contrast medium leakage mimicking intraventricular hemorrhage during intra-arterial 100% ethanol sclerotherapy into the posterolateral choroidal artery in a 5-year-old child with a ruptured AVM.32 While such a phenomenon is uncommon and not reported elsewhere, the neurointerventionalist should be aware of it, especially because many of the feeding arteries in this study involved arteries supplying the choroid plexus.

This study has several important limitations. The retrospective nature limits the generalizability of the results, and a selection bias may be present. In addition, there was no comparison group to determine whether ethanol sclerotherapy would achieve better results with similar or fewer complications in similar cases with the use of other embolic materials, such as n-BCA or Onyx. Selection of a comparison group of flow-related aneurysms for this series would be difficult and impractical, however, because the catheter positions in which ethanol was used in nearly all patients in this cases series precluded the safe or efficacious use of embolic agents. The authors recommend against a study that compares the efficacy and safety profile of ethanol sclerotherapy with embolic agents in the setting of endovascular AVM treatment.16 In addition, because this study included only patients with ruptured AVMs, the results cannot be generalized to unruptured cerebral AVMs. Given the small number of patients in this study, results should be confirmed in a larger prospective study. Gross pathology confirmation of aneurysm obliteration was not possible in this study, and evidence of obliteration is based solely on follow-up conventional angiography in 9/10 patients.

In conclusion, this study suggests that in a subset of ruptured cerebral AVMs, ethanol sclerotherapy of FAAs and INAs can be performed with a high degree of technical success and a low rate of complications.

Footnotes

  • Disclosures: Christopher F. Dowd—UNRELATED: Other: MicroVention,* Comments: Chief Adjudicator, Flow Redirection Intraluminal Device (FRED) Trial. *Money paid to the institution.

  • Paper previously presented at: Annual Meeting of the Society of Neurointerventional Surgery, July 27–30, 2015; San Francisco, California.

REFERENCES

  1. 1.↵
    1. Perata HJ,
    2. Tomsick TA,
    3. Tew JM Jr.
    . Feeding artery pedicle aneurysms: association with parenchymal hemorrhage and arteriovenous malformation in the brain. J Neurosurg 1994;80:631–34 doi:10.3171/jns.1994.80.4.0631 pmid:8151340
    CrossRefPubMed
  2. 2.↵
    1. Redekop G,
    2. TerBrugge K,
    3. Montanera W, et al
    . Arterial aneurysms associated with cerebral arteriovenous malformations: classification, incidence, and risk of hemorrhage. J Neurosurg 1998;89:539–46 doi:10.3171/jns.1998.89.4.0539 pmid:9761046
    CrossRefPubMed
  3. 3.↵
    1. Pollock BE,
    2. Flickinger JC,
    3. Lunsford LD, et al
    . Factors that predict the bleeding risk of cerebral arteriovenous malformations. Stroke 1996;27:1–6 doi:10.1161/01.STR.27.1.1 pmid:8553382
    Abstract/FREE Full Text
  4. 4.↵
    1. Spetzler RF,
    2. Martin NA,
    3. Carter LP, et al
    . Surgical management of large AVM's by staged embolization and operative excision. J Neurosurg 1987;67:17–28 doi:10.3171/jns.1987.67.1.0017 pmid:3598668
    CrossRefPubMed
  5. 5.↵
    1. Gobin YP,
    2. Laurent A,
    3. Merienne L, et al
    . Treatment of brain arteriovenous malformations by embolization and radiosurgery. J Neurosurg 1996;85:19–28 doi:10.3171/jns.1996.85.1.0019 pmid:8683274
    CrossRefPubMed
  6. 6.↵
    1. Henkes H,
    2. Nahser HC,
    3. Berg-Dammer E, et al
    . Endovascular therapy of brain AVMs prior to radiosurgery. Neurol Res 1998;20:479–92 pmid:9713837
    PubMed
  7. 7.↵
    1. Richling B,
    2. Killer M
    . Endovascular management of patients with cerebral arteriovenous malformations. Neurosurg Clin N Am 2000;11:123–45, ix pmid:10565874
    PubMed
  8. 8.↵
    1. Jahan R,
    2. Murayama Y,
    3. Gobin YP, et al
    . Embolization of arteriovenous malformations with Onyx: clinicopathological experience in 23 patients. Neurosurgery 2001;48:984–95; discussion 995–987 doi:10.1097/00006123-200105000-00003 pmid:11334300
    CrossRefPubMed
  9. 9.↵
    1. Pierot L,
    2. Januel AC,
    3. Herbreteau D, et al
    . Endovascular treatment of brain arteriovenous malformations using Onyx: preliminary results of a prospective multicenter study. Interv Neuroradiol 2005;11:159–64 pmid:20584470
    Abstract/FREE Full Text
  10. 10.↵
    1. van Rooij WJ,
    2. Sluzewski M,
    3. Beute GN
    . Brain AVM embolization with Onyx. AJNR Am J Neuroradiol 2007;28:172–77; discussion 178 pmid:17213451
    Abstract/FREE Full Text
  11. 11.↵
    1. Sorimachi T,
    2. Koike T,
    3. Takeuchi S, et al
    . Embolization of cerebral arteriovenous malformations achieved with polyvinyl alcohol particles: angiographic reappearance and complications. AJNR Am J Neuroradiol 1999;20:1323–28 pmid:10472993
    Abstract/FREE Full Text
  12. 12.↵
    1. Yakes WF
    . Endovascular management of high-flow arteriovenous malformations. Semin Intervent Radiol 2004;21:49–58 doi:10.1055/s-2004-831405 pmid:21331109
    CrossRefPubMed
  13. 13.↵
    1. Pekkola J,
    2. Lappalainen K,
    3. Vuola P, et al
    . Head and neck arteriovenous malformations: results of ethanol sclerotherapy. AJNR Am J Neuroradiol 2013;34:198–204 doi:10.3174/ajnr.A3180 pmid:22766677
    Abstract/FREE Full Text
  14. 14.↵
    1. Vogelzang RL,
    2. Atassi R,
    3. Vouche M, et al
    . Ethanol embolotherapy of vascular malformations: clinical outcomes at a single center. J Vasc Interv Radiol 2014;25:206–13; quiz 214 doi:10.1016/j.jvir.2013.10.055 pmid:24461130
    CrossRefPubMed
  15. 15.↵
    1. Lee BB,
    2. Do YS,
    3. Yakes W, et al
    . Management of arteriovenous malformations: a multidisciplinary approach. J Vasc Surg 2004;39:590–600 doi:10.1016/j.jvs.2003.10.048 pmid:14981454
    CrossRefPubMed
  16. 16.↵
    1. Yakes WF,
    2. Krauth L,
    3. Ecklund J, et al
    . Ethanol endovascular management of brain arteriovenous malformations: initial results. Neurosurgery 1997;40:1145–52; discussion 1152–1144 doi:10.1097/00006123-199706000-00005 pmid:9179886
    CrossRefPubMed
  17. 17.↵
    1. Wong GA,
    2. Armstrong DC,
    3. Robertson JM
    . Cardiovascular collapse during ethanol sclerotherapy in a pediatric patient. Paediatr Anaesth 2006;16:343–46 doi:10.1111/j.1460-9592.2005.01710.x pmid:16490104
    CrossRefPubMed
  18. 18.↵
    1. Do YS,
    2. Yakes WF,
    3. Shin SW, et al
    . Ethanol embolization of arteriovenous malformations: interim results. Radiology 2005;235:674–82 doi:10.1148/radiol.2352040449 pmid:15858106
    CrossRefPubMed
  19. 19.↵
    1. Shin BS,
    2. Do YS,
    3. Lee BB, et al
    . Multistage ethanol sclerotherapy of soft-tissue arteriovenous malformations: effect on pulmonary arterial pressure. Radiology 2005;235:1072–77 doi:10.1148/radiol.2353040903 pmid:15833991
    CrossRefPubMed
  20. 20.↵
    1. Choi YH,
    2. Han MH,
    3. O-Ki K, et al
    . Craniofacial cavernous venous malformations: percutaneous sclerotherapy with use of ethanolamine oleate. J Vasc Interv Radiol 2002;13:475–82 doi:10.1016/S1051-0443(07)61527-9 pmid:11997355
    CrossRefPubMed
  21. 21.↵
    1. de Lorimier AA
    . Sclerotherapy for venous malformations. J Pediatr Surg 1995;30:188–93; discussion 194 doi:10.1016/0022-3468(95)90558-8 pmid:7738736
    CrossRefPubMed
  22. 22.↵
    1. Behnia R
    . Systemic effects of absolute alcohol embolization in a patient with a congenital arteriovenous malformation of the lower extremity. Anesth Analg 1995;80:415–17 doi:10.1213/00000539-199502000-00037 pmid:7818135
    CrossRefPubMed
  23. 23.↵
    1. Garel L,
    2. Mareschal JL,
    3. Gagnadoux MF, et al
    . Fatal outcome after ethanol renal ablation in child with end-stage kidneys. AJR Am J Roentgenol 1986;146:593–94 doi:10.2214/ajr.146.3.593 pmid:3511641
    CrossRefPubMed
  24. 24.↵
    1. Mason KP,
    2. Michna E,
    3. Zurakowski D, et al
    . Serum ethanol levels in children and adults after ethanol embolization or sclerotherapy for vascular anomalies. Radiology 2000;217:127–32 doi:10.1148/radiology.217.1.r00se30127 pmid:11012433
    CrossRefPubMed
  25. 25.↵
    1. Stefanutto TB,
    2. Halbach V
    . Bronchospasm precipitated by ethanol injection in arteriovenous malformation. AJNR Am J Neuroradiol 2003;24:2050–51 pmid:14625231
    Abstract/FREE Full Text
  26. 26.↵
    1. Spetzler RF,
    2. Martin NA
    . A proposed grading system for arteriovenous malformations. J Neurosurg 1986;65:476–83 doi:10.3171/jns.1986.65.4.0476 pmid:3760956
    CrossRefPubMed
  27. 27.↵
    1. Yakes WF,
    2. Rossi P,
    3. Odink H
    . How I do it: arteriovenous malformation management. Cardiovasc Intervent Radiol 1996;19:65–71 doi:10.1007/BF02563895 pmid:8729181
    CrossRefPubMed
  28. 28.↵
    1. Yakes WF,
    2. Haas DK,
    3. Parker SH, et al
    . Symptomatic vascular malformations: ethanol embolotherapy. Radiology 1989;170:1059–66 doi:10.1148/radiology.170.3.2916057 pmid:2916057
    CrossRefPubMed
  29. 29.↵
    1. Legiehn GM,
    2. Heran MK
    . A step-by-step practical approach to imaging diagnosis and interventional radiologic therapy in vascular malformations. Semin Intervent Radiol 2010;27:209–31 doi:10.1055/s-0030-1253521 pmid:21629410
    CrossRefPubMed
  30. 30.↵
    1. Mason KP,
    2. Neufeld EJ,
    3. Karian VE, et al
    . Coagulation abnormalities in pediatric and adult patients after sclerotherapy or embolization of vascular anomalies. AJR Am J Roentgenol 2001;177:1359–63 doi:10.2214/ajr.177.6.1771359 pmid:11717083
    CrossRefPubMed
  31. 31.↵
    1. Unnikrishnan KP,
    2. Sinha PK,
    3. Sriganesh K, et al
    . Case report: alterations in bispectral index following absolute alcohol embolization in a patient with intracranial arteriovenous malformation. Can J Anaesth 2007;54:908–11 doi:10.1007/BF03026795 pmid:17975236
    CrossRefPubMed
  32. 32.↵
    1. Phatouros CC,
    2. Halbach VV,
    3. Malek AM, et al
    . Intraventricular contrast medium leakage during ethanol embolization of an arteriovenous malformation. AJNR Am J Neuroradiol 1999;20:1329–32 pmid:10472994
    Abstract/FREE Full Text
  • Received June 25, 2015.
  • Accepted after revision August 10, 2015.
  • © 2016 by American Journal of Neuroradiology
View Abstract
PreviousNext
Back to top

In this issue

American Journal of Neuroradiology: 37 (4)
American Journal of Neuroradiology
Vol. 37, Issue 4
1 Apr 2016
  • Table of Contents
  • Index by author
  • Complete Issue (PDF)
Advertisement
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on American Journal of Neuroradiology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Superselective Intra-Arterial Ethanol Sclerotherapy of Feeding Artery and Nidal Aneurysms in Ruptured Cerebral Arteriovenous Malformations
(Your Name) has sent you a message from American Journal of Neuroradiology
(Your Name) thought you would like to see the American Journal of Neuroradiology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Superselective Intra-Arterial Ethanol Sclerotherapy of Feeding Artery and Nidal Aneurysms in Ruptured Cerebral Arteriovenous Malformations
F. Settecase, S.W. Hetts, A.D. Nicholson, M.R. Amans, D.L. Cooke, C.F. Dowd, R.T. Higashida, V.V. Halbach
American Journal of Neuroradiology Apr 2016, 37 (4) 692-697; DOI: 10.3174/ajnr.A4584

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Superselective Intra-Arterial Ethanol Sclerotherapy of Feeding Artery and Nidal Aneurysms in Ruptured Cerebral Arteriovenous Malformations
F. Settecase, S.W. Hetts, A.D. Nicholson, M.R. Amans, D.L. Cooke, C.F. Dowd, R.T. Higashida, V.V. Halbach
American Journal of Neuroradiology Apr 2016, 37 (4) 692-697; DOI: 10.3174/ajnr.A4584
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Purchase

Jump to section

  • Article
    • Abstract
    • ABBREVIATIONS:
    • Results
    • Discussion
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • References
  • PDF

Related Articles

  • PubMed
  • Google Scholar

Cited By...

  • Republished: Transvenous ethanol sclerotherapy of feeding arteries for treatment of a dural arteriovenous fistula
  • Transvenous ethanol sclerotherapy of feeding arteries for treatment of a dural arteriovenous fistula
  • Crossref (16)
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Arterial aneurysms associated with arteriovenous malformations of the brain: classification, incidence, risk of hemorrhage, and treatment—a systematic review
    Federico Cagnazzo, Waleed Brinjikji, Giuseppe Lanzino
    Acta Neurochirurgica 2016 158 11
  • Endovascular treatment in the multimodality management of brain arteriovenous malformations: report of the Society of NeuroInterventional Surgery Standards and Guidelines Committee
    Reade De Leacy, Sameer A Ansari, Clemens M Schirmer, Daniel L Cooke, Charles J Prestigiacomo, Ketan R Bulsara, Steven W Hetts
    Journal of NeuroInterventional Surgery 2022 14 11
  • Targeted Embolization of Aneurysms Associated With Brain Arteriovenous Malformations at High Risk for Surgical Resection: A Case-Control Study
    Matthew D Alexander, Daniel S Hippe, Daniel L Cooke, Danial K Hallam, Steven W Hetts, Helen Kim, Michael T Lawton, Laligam N Sekhar, Louis J Kim, Basavaraj V Ghodke
    Neurosurgery 2018 82 3
  • Novel use of flow diversion for the treatment of aneurysms associated with arteriovenous malformations
    Craig Kilburg, Philipp Taussky, M. Yashar S. Kalani, Min S. Park
    Neurosurgical Focus 2017 42 6
  • Endovascular Management of Arteriovenous Malformation–Associated Intracranial Aneurysms: A Systematic Literature Review
    Mohamed E. El-Abtah, Jordan C. Petitt, Ahmed Kashkoush, Rebecca Achey, Mark D. Bain, Nina Z. Moore
    World Neurosurgery 2022 164
  • Atlas of Nervous System Vascular Malformations: A Systematic Review
    Carlos Castillo-Rangel, Gerardo Marín, Karla Aketzalli Hernandez-Contreras, Cristofer Zarate-Calderon, Micheel Merari Vichi-Ramirez, Wilmar Cortez-Saldias, Marco Antonio Rodriguez-Florido, Ámbar Elizabeth Riley-Moguel, Omar Pichardo, Osvaldo Torres-Pineda, Helena G. Vega-Quesada, Ramiro Lopez-Elizalde, Jaime Ordoñez-Granja, Hugo Helec Alvarado-Martinez, Luis Andrés Vega-Quesada, Gonzalo Emiliano Aranda-Abreu
    Life 2022 12 8
  • Brain Arteriovenous Malformations
    Emmanuel Houdart, Marc Antoine Labeyrie, Stéphanie Lenck, Jean Pierre Saint-Maurice
    2017
  • Trans-ophthalmic arterial ethanol embolotherapy for arteriovenous malformations: a single-center experience
    Li-xin Su, Xin-yu Li, Ming-zhe Wen, De-ming Wang, Xin-dong Fan, Xi-tao Yang
    Neurosurgical Review 2022 45 4
  • Alcohol
    Reactions Weekly 2017 1641 1
  • Cerebrovascular and Endovascular Neurosurgery
    Matthew D. Alexander, Daniel L. Cooke, Steven W. Hetts
    2018

More in this TOC Section

INTERVENTIONAL

  • Partial (SAVE) versus Complete (Solumbra) Stent Retriever Retraction Technique for Mechanical Thrombectomy: A Randomized In Vitro Study
  • Intra-Arterial Thrombolysis is Associated with Delayed Reperfusion of Remaining Vessel Occlusions following Incomplete Thrombectomy
  • Contrast Injection from an Intermediate Catheter Placed in an Intradural Artery is Associated with Contrast-Induced Encephalopathy following Neurointervention
Show more INTERVENTIONAL

ADULT BRAIN

  • Systematic Literature Review of Machine Learning Algorithms Using Pretherapy Radiologic Imaging for Glioma Molecular Subtype Prediction
  • Cortical and Subcortical Brain Atrophy Assessment Using Simple Measures on NCCT Compared with MRI in Acute Stroke
  • Prospective, Longitudinal Study of Clinical Outcome and Morphometric Posterior Fossa Changes after Craniocervical Decompression for Symptomatic Chiari I Malformation
Show more ADULT BRAIN

PEDIATRICS

  • Fetal Brain Growth in the Early Second Trimester
  • Dual-Layer Detector Head CT to Maintain Image Quality While Reducing the Radiation Dose in Pediatric Patients
  • Arterial Spin-Labeling in the Assessment of Pediatric Nontraumatic Orbital Lesions
Show more PEDIATRICS

Similar Articles

Advertisement

News and Updates

  • Lucien Levy Best Research Article Award
  • Thanks to our 2022 Distinguished Reviewers

Resources

  • Evidence-Based Medicine Level Guide
  • AJNR Podcast Archive
  • Librarian Resources
  • Terms and Conditions

Opportunities

  • Get Peer Review Credit from Publons

American Society of Neuroradiology

  • Neurographics
  • ASNR Annual Meeting
  • Fellowship Portal

© 2023 by the American Society of Neuroradiology | Print ISSN: 0195-6108 Online ISSN: 1936-959X

Powered by HighWire